Gabather AB (SE:GABA)

:GABA

GABA

Gabather AB

RESEARCH TOOLSreports

Want to see SE:GABA full AI Analyst Report?

Gabather AB (GABA) Price & Analysis

0 Followers

GABA Stock Chart & Stats

kr0.03

>-kr0.01(-12.89%)

At close: Mar 06 4:00 PM EST

kr0.03

>-kr0.01(-12.89%)

Day’s Range― - ―

52-Week Rangekr0.02 - kr0.13

Previous CloseN/A

Volume42.79K

Average Volume (3M)488.51K

Market Cap

kr17.60M

Enterprise Valuekr5.31M

Total Cash (Recent Filing)kr3.14M

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)―

Beta1.13

Next Earnings

May 28, 2026

EPS Estimate

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.00

Shares Outstanding491,634,160

10 Day Avg. Volume541,248

30 Day Avg. Volume488,507

Financial Highlights & Ratios

PEG Ratio0.01

Price to Book (P/B)-6.10

Price to Sales (P/S)0.00

P/FCF Ratio-0.73

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Zero Debt / Low LeverageA zero-debt balance sheet materially reduces refinancing and fixed-charge risk for a pre-revenue biotech. This structural strength preserves financial flexibility to fund R&D, pursue partnerships or absorb temporary cash shortfalls without added interest burdens.

Focused GABAA CNS ExpertiseA concentrated scientific focus on small-molecule GABAA receptor modulation builds durable technical know-how and a clear clinical/indication strategy. Specialization can yield differentiated assets, streamline development choices, and increase appeal to licensing partners in persistent CNS markets.

Improving Net Loss TrendA multi-year narrowing of net losses indicates stronger cost control or program prioritization. This durable improvement can extend runway per financing event, reduce future dilution needs, and signal management capability in aligning spending with development priorities.

Bears Say

Pre-revenue With Persistent Cash BurnThe absence of revenue combined with ongoing negative operating and free cash flow creates structural reliance on external financing. Long-term program execution and timeline certainty hinge on securing capital, increasing execution and dilution risk for stakeholders.

Negative Equity / Eroded Capital BasePersistent accumulated losses producing negative equity signal an eroded capital base. This limits ability to access traditional debt, can deter partnership terms, and raises solvency concerns if losses persist, constraining long-term strategic optionality.

Volatile Cash Usage And Funding RelianceMaterial year-to-year swings in cash burn increase runway uncertainty and complicate planning. Volatile cash usage heightens the probability of interim financings, which can dilute equity holders and force reprioritization or delay of development programs.

GABA FAQ

What was Gabather AB’s price range in the past 12 months?

Gabather AB lowest stock price was kr0.02 and its highest was kr0.13 in the past 12 months.

What is Gabather AB’s market cap?

Gabather AB’s market cap is kr17.60M.

When is Gabather AB’s upcoming earnings report date?

Gabather AB’s upcoming earnings report date is May 28, 2026 which is in 28 days.

How were Gabather AB’s earnings last quarter?

Gabather AB released its earnings results on Feb 26, 2026. The company reported kr0 earnings per share for the quarter, the consensus estimate of kr0 by kr0.

Is Gabather AB overvalued?

According to Wall Street analysts Gabather AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Gabather AB pay dividends?

Gabather AB does not currently pay dividends.

What is Gabather AB’s EPS estimate?

Gabather AB’s EPS estimate is 0.

How many shares outstanding does Gabather AB have?

Gabather AB has 491,634,160 shares outstanding.

What happened to Gabather AB’s price movement after its last earnings report?

Gabather AB reported an EPS of kr0 in its last earnings report, expectations of kr0. Following the earnings report the stock price went up 18.519%.

Which hedge fund is a major shareholder of Gabather AB?

Currently, no hedge funds are holding shares in SE:GABA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Gabather AB

Gabather AB (publ) develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company was incorporated in 2014 and is based in Södertälje Sweden.